|

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

RECRUITINGSponsored by Proteocyte Diagnostics Inc.
Actively Recruiting
SponsorProteocyte Diagnostics Inc.
Started2015-03-12
Est. completion2025-12-31
Eligibility
Age15 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04622462

Summary

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Eligibility

Age: 15 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma

Exclusion Criteria:

* Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy

Conditions2

CancerOral Neoplasm

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.